Wu Yan, Eigenbrot Charles, Liang Wei-Ching, Stawicki Scott, Shia Steven, Fan Bin, Ganesan Rajkumar, Lipari Michael T, Kirchhofer Daniel
Departments of Antibody Engineering and Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19784-9. doi: 10.1073/pnas.0708251104. Epub 2007 Dec 5.
To better understand how the relatively flat antigen-combining sites of antibodies interact with the concave shaped substrate-binding clefts of proteases, we determined the structures of two antibodies in complex with the trypsin-like hepatocyte growth-factor activator (HGFA). The two inhibitory antibodies, Ab58 and Ab75, were generated from a human Fab phage display library with synthetic diversity in the three complementarity determining regions (H1, H2, and H3) of the heavy chain, mimicking the natural diversity of the human Ig repertoire. Biochemical studies and the structures of the Fab58:HGFA (3.5-A resolution) and the Fab75:HGFA (2.2-A resolution) complexes revealed that Ab58 obstructed substrate access to the active site, whereas Ab75 allosterically inhibited substrate hydrolysis. In both cases, the antibodies interacted with the same protruding element (99-loop), which forms part of the substrate-binding cleft. Ab58 inserted its H1 and H2 loops in the cleft to occupy important substrate interaction sites (S3 and S2). In contrast, Ab75 bound at the backside of the cleft to a region corresponding to thrombin exosite II, which is known to interact with allosteric effector molecules. In agreement with the structural analysis, binding assays with active site inhibitors and enzymatic assays showed that Ab58 is a competitive inhibitor, and Ab75 is a partial competitive inhibitor. These results provide structural insight into antibody-mediated protease inhibition. They suggest that unlike canonical inhibitors, antibodies may preferentially target protruding loops at the rim of the substrate-binding cleft to interfere with the catalytic machinery of proteases without requiring long insertion loops.
为了更好地理解抗体相对扁平的抗原结合位点如何与蛋白酶的凹形底物结合裂隙相互作用,我们确定了两种与类胰蛋白酶肝细胞生长因子激活剂(HGFA)形成复合物的抗体的结构。这两种抑制性抗体Ab58和Ab75是从人Fab噬菌体展示文库中产生的,其重链的三个互补决定区(H1、H2和H3)具有合成多样性,模拟了人类Ig库的天然多样性。生化研究以及Fab58:HGFA复合物(分辨率为3.5埃)和Fab75:HGFA复合物(分辨率为2.2埃)的结构表明,Ab58阻碍底物进入活性位点,而Ab75通过变构抑制底物水解。在这两种情况下,抗体都与构成底物结合裂隙一部分的同一个突出元件(99环)相互作用。Ab58将其H1和H2环插入裂隙中,占据重要的底物相互作用位点(S3和S2)。相比之下,Ab75结合在裂隙的背面,与凝血酶外位点II对应的区域结合,已知该区域与变构效应分子相互作用。与结构分析一致,用活性位点抑制剂进行的结合试验和酶活性试验表明,Ab58是竞争性抑制剂,Ab75是部分竞争性抑制剂。这些结果为抗体介导的蛋白酶抑制提供了结构上的见解。它们表明,与经典抑制剂不同,抗体可能优先靶向底物结合裂隙边缘的突出环,以干扰蛋白酶的催化机制,而无需长插入环。